There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.

Human Library – Reading People Through Their Life’s Experiences

Human beings have the innate desire to create and...

Interview with Ajit Singh, Chairman, ACG

Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan

Is Your Career Headed in the Right Direction?

Make Sure You're Moving in the Right Direction… Digital,...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Marketing

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Policies/Sales

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Strategy

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Frontline Managers

Articles by Vivek Hattangadi, Raja Reddy, K. Hariram, Satish Kota, P. S. Parameswaran, Gopal Kishore, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal and Mahendra Kumar Rai

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

Specially Designed Case Study based Modules for Pharma Marketing Professionals

More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences. With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers. Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.